BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-induced migration, angiogenesis and permeability in tumor-derived endothelial cells.
Sign Up to like & getrecommendations! Published in 2020 at "Immunology letters"
DOI: 10.1016/j.imlet.2020.12.007
Abstract: Tumor angiogenesis plays a vital role in carcinogenesis, cancer progression, and metastasis. Lipoxin A4 (LXA4) is an endogenously-produced family of effective anti-inflammatory with a potent inhibitory effect on angiogenesis. However, BML-111, a LXA4 agonist, its… read more here.
Keywords: angiogenesis; permeability; vegf cocl2; bml 111 ... See more keywords